Greenville, NCNCT05625659Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Greenville, NC

Access cutting-edge breast cancer treatment through this clinical trial at a research site in Greenville. Study-provided care at no cost to qualified participants.

Sponsored by American College of Radiology

Quick Self-Assessment

See if you qualify for this Greenville location

Preparing your pre-screening questions…

Expert Care in Greenville

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Greenville Location

Check if you qualify for this breast cancer clinical trial in Greenville, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Greenville

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Greenville site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Greenville

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.

Sponsor: American College of Radiology

Who Can Participate

Inclusion Criteria

1\. Women must have mammographically dense breasts, ACR BI-RADS® lexicon categories c or d (heterogeneous or extreme fibroglandular tissue) on their most recent prior screening.
2\. Women agree to not undergo whole breast screening ultrasound for the duration of the trial until the year 2 standard of care imaging.
3\. Women must not have symptoms or signs of benign or malignant breast disease (e.g., bloody, or clear nipple discharge, breast lump, focal breast pain).
4\. Women must be able to undergo intravenous (IV) administration of iodinated contrast (e.g., no contraindication to intravenous contrast administration for Omnipaque \[iohexol\], and no known allergy-like reaction to iodine or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology \[ACR\]: https://www.acr.org/-/media/ACR/files/clinical-resources/contrast\_media.pdf).
5\. Women must not be pregnant or breast-feeding. All females of childbearing potential who are uncertain if they could be pregnant or may be pregnant or as per local site standard of practice in women undergoing DBT and CESM must have a negative blood test or urine pregnancy test prior to Omnipaque (iohexol) administration. A female of childbearing potential is any woman, regardless of sexual orientation, sexual identity or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
6\. Women of childbearing potential must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the following year until the Year 1 DBT and CESM studies are performed.

Exclusion Criteria

1\. Women currently undergoing treatment for breast cancer, or planning surgery for a high-risk lesion (ADH, ALH, LCIS, papilloma, radial scar).
2\. Women who have had the following are not eligible:
a mammogram less than 11 months prior to study entry.
screening breast ultrasound within 11 months prior to study entry.
breast MRI less than 36 months prior to study entry.
contrast-enhanced spectral mammography less than 36 months prior to study entry.
molecular breast imaging (MBI) less than 36 months prior to study entry.
breast prosthetic implants (silicone or saline).
suspected of being at high-risk for breast cancer, as defined by the ACS breast MR screening recommendations (lifetime risk of ≥20%-25%) unless they are unable to undergo an MRI. (Reference Appendix I)
a history of sickle cell disease.
3\. Women with known or suspected renal impairment. Requirements for glomerular filtration rate (GFR) determination prior to IV iodinated contrast administration are determined by local site standard practice. Criteria that should be considered include, but are not limited to, the following:
Age \>60 years old
History of renal disease, including dialysis, kidney transplant, single kidney, renal cancer, and renal surgery
History of hypertension requiring medical therapy
History of diabetes mellitus
Use of metformin or metformin-containing drug combinations
4\. Women who are pregnant, breast feeding, or planning to become pregnant from screening until 30 days after the last administration of Omnipaque (iohexol).
5\. Large breasted women that require multiple images per standard view of the breast (Tiling) as determined by their most recent mammogram.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Greenville?

Yes, this clinical trial (NCT05625659) has an active research site in Greenville, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Greenville, NC

If you're searching for breast cancer treatment options in Greenville, NC, this clinical trial (NCT05625659) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Greenville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Greenville, NC

See all breast cancer clinical trials recruiting in Greenville — not just this study.

Browse Breast Cancer Trials in Greenville →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Greenville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Greenville, NC